BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
FRA:BSX - Deutsche Boerse Ag - US1011371077 - Common Stock - Currency: EUR
BSX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 55 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of BSX get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, BSX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
BSX had a positive operating cash flow in the past year.
Of the past 5 years BSX 4 years were profitable.
In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 4.71%, BSX is doing good in the industry, outperforming 70.59% of the companies in the same industry.
BSX has a better Return On Equity (8.66%) than 66.67% of its industry peers.
BSX's Return On Invested Capital of 6.31% is fine compared to the rest of the industry. BSX outperforms 68.63% of its industry peers.
BSX had an Average Return On Invested Capital over the past 3 years of 5.38%. This is below the industry average of 8.18%.
The 3 year average ROIC (5.38%) for BSX is below the current ROIC(6.31%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.66% | ||
| ROIC | 6.31% |
ROA(3y)3.17%
ROA(5y)4.9%
ROE(3y)5.91%
ROE(5y)10.17%
ROIC(3y)5.38%
ROIC(5y)4.7%
1.3 Margins
BSX's Profit Margin of 11.27% is fine compared to the rest of the industry. BSX outperforms 78.43% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 18.06%, BSX belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
BSX's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 69.09%, BSX is doing good in the industry, outperforming 74.51% of the companies in the same industry.
In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.06% | ||
| PM (TTM) | 11.27% | ||
| GM | 69.09% |
OM growth 3Y23.29%
OM growth 5Y-0.75%
PM growth 3YN/A
PM growth 5Y-8.31%
GM growth 3Y2.2%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
The number of shares outstanding for BSX has been increased compared to 1 year ago.
BSX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BSX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.02 indicates that BSX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.02, BSX belongs to the top of the industry, outperforming 88.24% of the companies in the same industry.
BSX has a debt to FCF ratio of 5.05. This is a neutral value as BSX would need 5.05 years to pay back of all of its debts.
BSX has a Debt to FCF ratio of 5.05. This is in the better half of the industry: BSX outperforms 70.59% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that BSX is not too dependend on debt financing.
BSX has a Debt to Equity ratio (0.45) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 6.02 |
ROIC/WACC0.71
WACC8.83%
2.3 Liquidity
BSX has a Current Ratio of 1.48. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
BSX has a Current ratio of 1.48. This is in the lower half of the industry: BSX underperforms 62.75% of its industry peers.
A Quick Ratio of 1.02 indicates that BSX should not have too much problems paying its short term obligations.
BSX has a Quick ratio (1.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.59%, which is quite good.
Measured over the past 5 years, BSX shows a small growth in Earnings Per Share. The EPS has been growing by 6.73% on average per year.
The Revenue has grown by 15.65% in the past year. This is quite good.
The Revenue has been growing slightly by 7.71% on average over the past years.
EPS 1Y (TTM)18.59%
EPS 3Y28.77%
EPS 5Y6.73%
EPS Q2Q%26%
Revenue 1Y (TTM)15.65%
Revenue growth 3Y12.83%
Revenue growth 5Y7.71%
Sales Q2Q%19.34%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.40% yearly.
Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 11.76% on average per year.
EPS Next Y21.26%
EPS Next 2Y17.34%
EPS Next 3Y16.15%
EPS Next 5Y14.4%
Revenue Next Year17.61%
Revenue Next 2Y15.28%
Revenue Next 3Y13.57%
Revenue Next 5Y11.76%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 43.14, the valuation of BSX can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of BSX is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 28.64. BSX is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 36.07, BSX can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, BSX is valued a bit more expensive than the industry average as 62.75% of the companies are valued more cheaply.
BSX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 24.51, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.14 | ||
| Fwd PE | 36.07 |
4.2 Price Multiples
BSX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. BSX is more expensive than 60.78% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSX is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 69.6 | ||
| EV/EBITDA | 38.58 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSX does not grow enough to justify the current Price/Earnings ratio.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
BSX's earnings are expected to grow with 16.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.03
PEG (5Y)6.41
EPS Next 2Y17.34%
EPS Next 3Y16.15%
5. Dividend
5.1 Amount
BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BOSTON SCIENTIFIC CORP
FRA:BSX (1/22/2025, 7:00:00 PM)
97.5
+0.5 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners92.66%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap143.70B
Analysts84.21
Price Target98.6 (1.13%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.02
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.03%
Min EPS beat(2)5.79%
Max EPS beat(2)6.28%
EPS beat(4)4
Avg EPS beat(4)6.62%
Min EPS beat(4)5.79%
Max EPS beat(4)8.11%
EPS beat(8)8
Avg EPS beat(8)5.81%
EPS beat(12)11
Avg EPS beat(12)3.94%
EPS beat(16)14
Avg EPS beat(16)3.03%
Revenue beat(2)2
Avg Revenue beat(2)2.34%
Min Revenue beat(2)1.53%
Max Revenue beat(2)3.16%
Revenue beat(4)4
Avg Revenue beat(4)2.73%
Min Revenue beat(4)1.53%
Max Revenue beat(4)3.6%
Revenue beat(8)7
Avg Revenue beat(8)2.31%
Revenue beat(12)9
Avg Revenue beat(12)1.61%
Revenue beat(16)11
Avg Revenue beat(16)1.22%
PT rev (1m)3.35%
PT rev (3m)21.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.11%
EPS NY rev (1m)0%
EPS NY rev (3m)2.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.36%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)1.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.14 | ||
| Fwd PE | 36.07 | ||
| P/S | 9.43 | ||
| P/FCF | 69.6 | ||
| P/OCF | 51.11 | ||
| P/B | 7.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 38.58 |
EPS(TTM)2.26
EY2.32%
EPS(NY)2.7
Fwd EY2.77%
FCF(TTM)1.4
FCFY1.44%
OCF(TTM)1.91
OCFY1.96%
SpS10.34
BVpS13.45
TBVpS-0.05
PEG (NY)2.03
PEG (5Y)6.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.66% | ||
| ROCE | 8.93% | ||
| ROIC | 6.31% | ||
| ROICexc | 6.85% | ||
| ROICexgc | 22.87% | ||
| OM | 18.06% | ||
| PM (TTM) | 11.27% | ||
| GM | 69.09% | ||
| FCFM | 13.55% |
ROA(3y)3.17%
ROA(5y)4.9%
ROE(3y)5.91%
ROE(5y)10.17%
ROIC(3y)5.38%
ROIC(5y)4.7%
ROICexc(3y)5.62%
ROICexc(5y)4.89%
ROICexgc(3y)18.15%
ROICexgc(5y)15.7%
ROCE(3y)7.61%
ROCE(5y)6.65%
ROICexcg growth 3Y41.88%
ROICexcg growth 5Y-27.21%
ROICexc growth 3Y32.52%
ROICexc growth 5Y-5.79%
OM growth 3Y23.29%
OM growth 5Y-0.75%
PM growth 3YN/A
PM growth 5Y-8.31%
GM growth 3Y2.2%
GM growth 5Y-0.42%
F-Score7
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 2.25 | ||
| Cap/Depr | 63.21% | ||
| Cap/Sales | 4.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 71.49% | ||
| Profit Quality | 120.25% | ||
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | 6.02 |
F-Score7
WACC8.83%
ROIC/WACC0.71
Cap/Depr(3y)53.97%
Cap/Depr(5y)53.74%
Cap/Sales(3y)4.76%
Cap/Sales(5y)5.05%
Profit Quality(3y)131.32%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.59%
EPS 3Y28.77%
EPS 5Y6.73%
EPS Q2Q%26%
EPS Next Y21.26%
EPS Next 2Y17.34%
EPS Next 3Y16.15%
EPS Next 5Y14.4%
Revenue 1Y (TTM)15.65%
Revenue growth 3Y12.83%
Revenue growth 5Y7.71%
Sales Q2Q%19.34%
Revenue Next Year17.61%
Revenue Next 2Y15.28%
Revenue Next 3Y13.57%
Revenue Next 5Y11.76%
EBIT growth 1Y20.21%
EBIT growth 3Y39.11%
EBIT growth 5Y6.9%
EBIT Next Year30.39%
EBIT Next 3Y19.57%
EBIT Next 5Y14.61%
FCF growth 1Y255.78%
FCF growth 3Y22.04%
FCF growth 5YN/A
OCF growth 1Y145.28%
OCF growth 3Y18.4%
OCF growth 5Y51.95%